Association of hyperemesis gravidarum with the risk of development of small for gestational age fetus
DOI:
https://doi.org/10.26641/2307-0404.2022.3.265938Keywords:
hyperemesis gravidarum, human chorionic gonadotropin, small for gestational age fetusAbstract
The goal of this study was to determine the association of hyperemesis gravidarum with the risk of development small for of fetus gestational age (SGA). Materials and methods. There were studied 327 pregnant women. The main group included 218 women with hyperemesis gravidarum, who were divided into two groups: 140 patients who were first hospitalized with hyperemesis gravidarum in the first trimester (up to 12 weeks of pregnancy) and 78 - who were first hospitalized with hyperemesis gravidarum in the second trimester (12-21 weeks of pregnancy). 109 pregnant women without vomiting were at control group. The diagnosis of SGA fetus was established on the basis of standard ultrasonic fetometry on the ALOKA SSD-1700. Determination of human serum chorionic gonadotropin (HCG) levels was performed at 15-20 weeks and was evaluated as MoM. The results were statistically analyzed using Statistica 10 (Serial Number: STA999K347150-W) and MEDCALC®. Results. In the main group, the SGA fetus was 3.4-fold more frequent compared with pregnant women in the control group (9.6% vs. 2.8%, p<0.05; OR=3.77; 95%CI:1,10-12.92). It was found that hyperemesis gravidarum in the first trimester does not affect the deviation of fetal weight deviations (p>0.05). However, hyperemesis gravidarum in pregnant women in the second trimester increases the risk of developing SGA fetus (OR=6.42; 95%CI 1.75-23.62; p<0.01) compared with control. Pregnant women with HCG≥2.5 MoM were 3.0-fold more likely to be diagnosed SGA fetus than with HCG<2.5 MoM (75.0% vs. 25.0%, p<0.001; OR=9.00; 95%CI:1.42-57.12) and 2.3-fold compared with the development of the normal fetus (75.0% vs. 33.3%, p<0.001; OR=6.00; 95%CI:1.47-24,4). Conclusion. Hyperemesis gravidarum in the second trimester of pregnancy and elevation of HCG level in the second trimester (≥2,5 МоМ) can be seen as markers of placental disfunction and high risk for SGA fetus.
References
Holovanova IA, Byelikova IV, Liakhova NO. [Basics of medical statistics]. Poltava: Educational manual. 2017:113. Ukrainian.
Lapovets LY, Lebed HB, Yastremska OO. [Clinical laboratory diagnostics]. 2-d ed. Kyiv: «Medytsyna»; 2021. Ukrainian.
Ostafiichuk SO. [Assessment of association of the Pro12Ala polymorphism of PPAR-γ gene with the risk of obstetric complications]. Zaporizkyi medychnyi zhurnal. 2019;5(116):631-7. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2019.5.179431
Romanenko TH, Melnychuk IP, Hymenko MV. [Fetal growth retardation (clinical lecture)]. Zdorovya zhinky. 2014;8(94):9-14. Ukrainian.
Bolin M, Akerud H, Cnattingius S, Stephansson O, Wikstrom A. Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOG. 2013;120:541-7. doi: https://doi.org/10.1111/1471-0528.12132
Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S745-61. doi: https://doi.org/10.1016/j.ajog.2017.11.577
Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, et al. Pla-centa and appetite genes GDF15 and IGFBP7 are as-sociated with hyperemesis gravidarum. Nat Commun. 2018;1(9):1-9.
doi: https://doi.org/10.1038/s41467-018-03258-0
Finken MJJ, van der Steen M, Smeets CCJ, Walenkamp MJE, de Bruin C, Hokken-Koelega ACS, Wit JM. Children born small for gestational age: differential diagnosis, molecular genetic evaluation, and implications. Endocrine Reviews. 2018 Dec;6(39):851-94. doi: https://doi.org/10.1210/er.2018-00083
Gobbo DGF, Yin Y, Choufani S, Butcher EA, Wei J, Rajcan-Separovic E, et al. Genomic imbalances in the placenta are associated with poor fetal growth. Mol Med. 2021;3(8):27. doi: 10.1186/ s10020-020-00253-4
Jennings LK, Krywko DM. Hyperemesis gravidarum. [Updated 2020 Nov 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532917
Lees CC, Stampalija T, Baschat AA, Costa F da Silva, Ferrazzi E, Figueras F, Hecher K, Kingdom J, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth res-triction. Ultrasound Obstet Gynecol. 2020;56:298-312. doi: https://doi.org/10.1002/uog.22134
Morokuma S, Shimokawa M, Kato K, Sanefuji M, Shibata E, Tsuji M, et al. Relationship between hypere¬mesis gravidarum and small-for-gestational-age in the Japanese population: the Japan Environment and Children’s Study (JECS). BMC Pregnancy Childbirth. 2016;1(16):247. doi: https://doi.org/10.1186/s12884-016-1041-6
Sharony R, Zipper O, Amichay K, Wiser A, Kid-ron D, Biron-Shental T, Maymon R. The magnitude of elevated maternal serum human chorionic gonadotropin and pregnancy complications. J Obstet Gynaecol. 2017;5(37):576-9. doi: https://doi.org/10.1080/01443615.2016.1268578
Thalava K, Manmatharaj, Prabhakar ER, Vaithialingam A. Human chorionic gonadotropin (Hcg) – levels in preeclampsia and hyperemesis. Global J Res Analysis. 2017 Feb;2(6):48-51. doi: https://doi.org/10.36106/gjra
Veenendaal MV, Van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011;118:1302-13. doi: https://doi.org/10.1111/j.1471-0528.2011.03023.x
Vikanes ÅV, Støer NC, Magnus P, Grjibovski AM. Hyperemesis gravidarum and pregnancy outcomes in the Norwegian mother and child cohort – a cohort study. BMC Pregnancy and Childbirth. 2013;13:169-177. doi: https://doi.org/10.1186/1471-2393-13-169
Yeaton-Massey A, Baer RJ, Rand L, Jelliffe-Pawlowski LL, Lyell DJ. Adverse pregnancy outcomes by degree of maternal serum analyte elevation: a retrospective cohort study. Am J Perinatol Rep. 2020;10:e369-pe379. doi: https://doi.org/10.1055/s-0040-1716741
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.